These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32379004)

  • 41. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
    Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
    Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models.
    Chen CY; Wang PY; Hutzen B; Sprague L; Swain HM; Love JK; Stanek JR; Boon L; Conner J; Cripe TP
    Sci Rep; 2017 May; 7(1):2396. PubMed ID: 28539588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
    Haines BB; Denslow A; Grzesik P; Lee JS; Farkaly T; Hewett J; Wambua D; Kong L; Behera P; Jacques J; Goshert C; Ball M; Colthart A; Finer MH; Hayes MW; Feau S; Kennedy EM; Lerner L; Quéva C
    Cancer Immunol Res; 2021 Mar; 9(3):291-308. PubMed ID: 33355229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
    Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
    Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potentiating prostate cancer immunotherapy with oncolytic viruses.
    Lee P; Gujar S
    Nat Rev Urol; 2018 Apr; 15(4):235-250. PubMed ID: 29434366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
    Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic Efficacy of an Oncolytic Influenza Virus Carrying an Antibody Against Programmed Cell Death 1 in Hepatocellular Carcinoma.
    Lei G; Li B; Yang H; Sun F; Li D; Yan J; Wang Y; Li R; Liu H; Zhang S; Li Y; Yang P
    Hum Gene Ther; 2022 Mar; 33(5-6):309-317. PubMed ID: 35018832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.
    Fend L; Yamazaki T; Remy C; Fahrner C; Gantzer M; Nourtier V; Préville X; Quéméneur E; Kepp O; Adam J; Marabelle A; Pitt JM; Kroemer G; Zitvogel L
    Cancer Res; 2017 Aug; 77(15):4146-4157. PubMed ID: 28536278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.
    Liu Z; Ravindranathan R; Kalinski P; Guo ZS; Bartlett DL
    Nat Commun; 2017 Mar; 8():14754. PubMed ID: 28345650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment.
    Kong D; Yang Z; Li G; Wu Q; Gu Z; Wan D; Zhang Q; Zhang X; Cheng S; Liu B; Zhang K; Zhang W
    BMC Med; 2022 Oct; 20(1):376. PubMed ID: 36310169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
    Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
    Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
    Babacan NA; Eroglu Z
    Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization.
    Cassidy T; Craig M
    PLoS Comput Biol; 2019 Nov; 15(11):e1007495. PubMed ID: 31774808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.
    Nair S; Mazzoccoli L; Jash A; Govero J; Bais SS; Hu T; Fontes-Garfias CR; Shan C; Okada H; Shresta S; Rich JN; Shi PY; Diamond MS; Chheda MG
    JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33232299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncolytic viruses to augment PD-1 inhibition in metastatic cutaneous squamous cell carcinoma.
    Pham JP; Zdanska O; Selga M; Javier J; O'Grady A; Chin V; Forstner D; Hsu E; Liu J
    J Dtsch Dermatol Ges; 2024 Jul; 22(7):1016-1018. PubMed ID: 38679789
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.